Knowledge Hub

Global Next-Generation Biologics Market to grow at a CAGR of 14.42% during 2016-2020

Press Release   •   Jan 23, 2017 04:54 EST

About Next-generation Biologics

According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings. Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.

Technavios analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Download Sample Copy of Report at http://www.marketresearchreports.biz/sample/sample/892950

Key vendors

F. Hofmann-La Roche

Novo Nordisk

Sanofi

Takeda Pharmaceuticals

Other prominent vendors

Aastrom Biosciences

AbbVie

AbGenomics

Acologix

ADC Therapeutics

Adocia

Agensys

AlloCure

AlloSource

ALMAC Group

Alphatec Spine

Ambrx

Amorcyte

Argos Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Avita Medical

Baxter

Bayer HealthCare

Bellicum Pharmaceuticals

BioCardia

Biocon

Biodel

BIOGENOMICS

BioLife Solutions

BioRestorative Therapies

BioTissue Technologies

Bluebird Bio

Boehringer Ingelheim

BrainStorm Cell Therapeutics

Calimmune

Capricor

CARBOGEN AMCIS

Cell Medica

Celldex Therapeutics

Celyad (Cardio3 BioSciences)

Cesca

CryoLife

CSL Behring

Cynata Therapeutics

Daiichi Sankyo

Dance Biopharm

Dendreon

Diasome Pharmaceuticals

DiscGenics

Endo Pharmaceuticals

Esperance Pharmaceuticals

Exsulin

Fate Therapeutics

Fibrocell Science

Formation Biologics

Forticell Bioscience

Fortress Biotech

Gamida Cell

GENEREX

Genmab

Geron

GlaxoSmithKline

Harvard Apparatus Regenerative Technology

Healthpoint

Histogen

Histogenics

Humacyte

Immunocellular Therapeutics

Immunogen

Integra LifeSciences

InVivo Therapeutics

ISTO Technologies

Juno Therapeutics

Juventas Therapeutics

Kairos Therapeutics

Kensey Nash

Kiadis Pharma

Kinetic Concept

Living Cell Technologies

MacroGenics

MannKind

MaxCyte

MedImmune

Medtronic

Mersana Therapeutics

Mesoblast

MiMedx

Nanofiber Solutions

Nanotope

Neuralstem

NewLink Genetics

NGM Biopharmaceuticals

Northwest Biotherapeutics

Novartis

NovaRx

Ocata Therapeutics

Opexa Therapeutics

Oramed Pharmaceuticals

Organovo

Orteq

Orthofix

Osiris Therapeutics

Osteotech

OXFORD BioTherapeutics

Pfizer

PhaseBio Pharmaceuticals

Pluristem Therapeutics

Prima BioMed

Q Therapeutics

ReproCELL

RhinoCyte

RTI Surgical

SanBio

Sangamo

Shire Regenerative Medicine

STEMCELL Technologies

Stemcentrx

Stratatech

Synthon Biopharmaceuticals

TEI Biosciences

Tengion

Thermalin Diabetes

TiGenix

Tissue Genesis

TissueGene

Tolerion

VentriNova

Vericel

VeroScience

ViaCyte

VistaGen Therapeutics

vTv Therapeutics

Wockhardt

XOMA

Zimmer Biomet

Zymeworks

Market driver

Advanced technological innovations

For a full, detailed list, view our report

Market challenge

Complexities in manufacturing of biologics

For a full, detailed list, view our report

Market trend

Development of gene and cell therapy-based products

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?